The new deal shifts to Quark the responsibility for conducting a planned phase IIb study of the drug. It also gives Pfizer the opportunity to pull out of the partnership, depending on the outcome of the trial.
Ambati and colleagues reported this month that Dicer1 depletion triggered the degeneration of retinal pigmented epithelium cells, a hallmark of the severest form of dry AMD, in human cells and mouse models.
OSU Medical Center will enroll patients who agree to join Coriell's personalized medicine project under the guidance of their primary care physician. The partners will study the impact of using genomic information in treating chronic conditions.
Pfizer and UCL to develop stem-cell therapies for AMD; Clarient licenses breast cancer biomarkers from Indiana U; Nanosys and Harvard to outlicense nanowire IP; Luminex settles with SUNY and U of Illinois, and more …